Hikma Pharmaceuticals (HKMPF)
(Delayed Data from OTC)
$25.16 USD
0.00 (0.00%)
Updated Oct 3, 2024 02:53 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
HKMPF 25.16 0.00(0.00%)
Will HKMPF be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for HKMPF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HKMPF
Hikma Pharmaceuticals (HKMPF) Upgraded to Buy: Here's What You Should Know
HKMPF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for HKMPF
Hikma Pharmaceuticals just upgraded at Berenberg, here's why
Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices
Hikma price target raised to 2,100 GBp from 2,000 GBp at Berenberg
Hikma Pharmaceuticals PLC (HKMPF) Q2 2024 Earnings Call Transcript
Hikma Pharmaceuticals PLC (HKMPF) Q2 2024 Pre-Recorded Presentation Transcript